Daily Sepsis Research Analysis
Today’s top sepsis papers span pathogen evolution, clinical phenotyping, and endothelial biomarkers. A novel hypervirulent, apigmented MRSA clone (ST3390) was mechanistically characterized; adult meningococcal disease shows distinct hemodynamic vs neurologic phenotypes with markedly different mortality; and early plasma sFlt-1 predicts sepsis-associated ARDS and mortality with ARDS mediating part of this risk.
Summary
Today’s top sepsis papers span pathogen evolution, clinical phenotyping, and endothelial biomarkers. A novel hypervirulent, apigmented MRSA clone (ST3390) was mechanistically characterized; adult meningococcal disease shows distinct hemodynamic vs neurologic phenotypes with markedly different mortality; and early plasma sFlt-1 predicts sepsis-associated ARDS and mortality with ARDS mediating part of this risk.
Research Themes
- Emergence and mechanistic virulence of bacterial clones relevant to sepsis
- Clinical phenotyping in invasive infections to stratify risk and guide therapy
- Endothelial/VEGF-pathway biomarkers linking sepsis to ARDS and mortality
Selected Articles
1. Emergence of ST3390: A novel apigmented MRSA clone from the CC5 Lineage.
This study identifies and mechanistically characterizes a rare, hypervirulent CC5-derived MRSA clone (ST3390) that lacks staphyloxanthin due to a conserved CrtN in-frame deletion and harbors unique hybrid SCCmec elements. ST3390 exhibits heightened neutrophil cytotoxicity and virulence in a murine sepsis model, indicating clinically relevant pathogenic potential despite apigmentation.
Impact: First comprehensive genomic and mechanistic description of a rare MRSA lineage with hypervirulence expands understanding of CC5 diversification and reveals actionable virulence features. It informs surveillance, pathogenesis, and potential therapeutic strategies targeting pigment pathways.
Clinical Implications: Enhanced surveillance for ST3390-like CC5 descendants is warranted, with attention to unique SCCmec mosaics and staphyloxanthin deficiency. Insights into pigment biosynthesis (CrtN) and neutrophil cytotoxicity pathways may guide adjunctive anti-virulence strategies.
Key Findings
- Identified a novel CC5 MRSA sequence type (ST3390) with only 65 recorded infections globally, including a Tampa cluster.
- All ST3390 strains are apigmented due to a conserved 6-amino-acid in-frame deletion in CrtN, abolishing staphyloxanthin.
- Approximately 90% of Tampa ST3390 strains carry unique hybrid SCCmec components (SCCmecIa, IIa, and/or VIII).
- ST3390 shows high cytotoxicity to human neutrophils and virulence in a murine sepsis model.
Methodological Strengths
- Integrated genomics, phenotyping, genetic complementation, and in vivo murine sepsis model.
- Functional assays (neutrophil-killing, blood viability) directly linked genotype to virulence phenotype.
Limitations
- Rare lineage with limited global cases; potential geographic clustering may limit generalizability.
- Preclinical models and in vitro assays cannot fully capture clinical disease severity or transmission dynamics.
Future Directions: Assess clinical outcomes and transmission in multi-center surveillance; explore anti-virulence strategies targeting staphyloxanthin/CrtN and neutrophil cytotoxicity; resolve SCCmec mosaic origins and implications for resistance.
BACKGROUND: One of the most successful and widely-distributed hospital-associated lineages of MRSA is clonal complex 5 (CC5). These strains are known for widespread antibiotic resistance, but less severe disease than CA-MRSA counterparts. Recently, CC5 descendant lineages have appeared globally with hypervirulent properties. Herein we identify and characterize a rare and novel CC5 MRSA sequence type, ST3390. METHODS: We used whole genome sequencing, alongside phenotypic characterizations, genetic complementation, blood viability- and neutrophil-killing assays, and a murine model of sepsis to study the pathogenic capabilities of ST3390 strains. RESULTS: To date, there have only been 65 recorded instances of infection caused by ST3390 globally, with 36 of those occurring in Tampa (TPA-ST3390). Genomic analysis of strains identified numerous spa-types, with a t010 cluster found only in our strains. Exploration of AMR genes detected the presence of unique hybrid SCCmec types, with ∼90% of Tampa strains possessing components of SCCmecIa, SCCmecIIa and/or SCCmecVIII. Phenotypically, all ST3390 strains lack the staphyloxanthin pigment, which is mediated by a conserved 6aa in frame deletion within the staphyloxanthin biosynthesis protein CrtN. TPA-ST3390 strains display high levels of cytotoxicity towards human neutrophils compared to other CC5 lineages, and are also virulent in animal models of infection. CONCLUSIONS: This is the first study to characterize the pathogenicity and genomic architecture of the rare MRSA lineage ST3390. Our work provides a deeper understanding of the clonal expansion of CC5, and the wider diversification of S. aureus isolates within patient populations.
2. Hemodynamic and neurological presentations of invasive meningococcal disease in adults: a nationwide study across 100+ French ICUs : The RETRO-MENINGO study.
In 654 adults with invasive meningococcal disease across 102 French ICUs, hemodynamic (septic) presentations required more organ support and had markedly higher 60-day mortality than neurological presentations (25.5% vs 4.7%). Early pre-ICU third-generation cephalosporin therapy was strongly protective, and serogroup distributions differed by phenotype (W135 in hemodynamic; B in neurological).
Impact: Clear phenotypic stratification with strong mortality separation and a modifiable protective factor (early cephalosporin) provides actionable guidance for triage and early management.
Clinical Implications: Rapid identification of hemodynamic phenotype should trigger immediate organ support escalation and early parenteral third-generation cephalosporin. Phenotype- and serogroup-aware strategies may improve outcomes and inform vaccination priorities.
Key Findings
- Hemodynamic presentation had higher 60-day mortality than neurological presentation (25.5% vs 4.7%; p<0.001).
- Independent mortality predictors included hemodynamic presentation (aOR 4.33), age >35 years, lactate >5 mmol/L, and symptom onset <24 h.
- Early pre-ICU parenteral third-generation cephalosporin was strongly protective (aOR 0.31).
- Serogroup W135 was more common in hemodynamic cases; serogroup B predominated in neurological cases.
Methodological Strengths
- Large, nationwide, multicentre cohort with standardized classification of presentations.
- Robust multivariable modeling of mortality with clinically relevant covariates.
Limitations
- Retrospective design with potential misclassification and unmeasured confounding.
- Findings from French ICUs may limit generalizability to different healthcare settings.
Future Directions: Prospective validation of phenotype-based care pathways, incorporation into early warning systems, and assessment of serogroup-specific vaccine and antibiotic strategies.
PURPOSE: Invasive meningococcal disease (IMD) is a rare but potentially fatal infection caused by Neisseria meningitidis. In adults requiring admission to intensive care unit (ICU), IMD typically presents with two distinct clinical presentations: neurological (meningitis) and hemodynamic (sepsis). These presentations are often conflated, despite the differences in pathophysiology and outcome. METHODS: RETRO-MENINGO is a nationwide, multicentre, retrospective cohort study conducted in 102 French ICUs between January 1, 2016, and December 31, 2024. Adults (≥ 18 years) admitted to the ICU with a microbiologically confirmed IMD were categorised as having either a neurological or a hemodynamic presentation according to the main reason for ICU admission. The primary outcome was day-60 mortality in each presentation. RESULTS: Of 654 patients (median age 33 years [IQR 21-56]; 63.5% without comorbidities), 407 (62%) had a neurological and 247 (38%) a hemodynamic presentation at ICU admission. Hemodynamic presentation was associated with older age (39.0 vs. 30.0 years; p = 0.001), immunosuppression (17.0% vs. 7.1%; p < 0.001), purpuric rash (55.9% vs. 43.7%; p = 0.003), earlier ICU admission (1 vs. 2 days; p = 0.001) and more frequent bacteremia (83.8% vs. 35.6%; p < 0.001). Serogroup B was predominant in neurological presentation, whereas serogroup W135 was more common in hemodynamic presentation. Compared to neurological presentation, hemodynamic presentation required more organ support (vasopressors, invasive mechanical ventilation, transfusions, renal replacement therapy) and had a significantly higher day-60 mortality (25.5% vs. 4.7%; p < 0.001). Hemodynamic presentation (aOR 4.33, 95% CI 2.26-8.62; p < 0.001), absence of comorbidities (aOR 2.21, 95% CI 1.19-4.23; p = 0.014), age > 35 years (aOR 3.65, 95% CI 1.73-6.07; p < 0.001), arterial lactate level > 5 mmol/L (aOR 2.60, 95% CI 1.43-4.77; p = 0.002) and symptom onset < 24 h (aOR 1.90, 95% CI 1.00-3.55; p = 0.040) were independently associated with day-60 mortality, while early administration of a parenteral third-generation cephalosporin prior to ICU admission was strongly protective (aOR 0.31, 95% CI 0.18-0.55; p < 0.001). CONCLUSION: Neurological and hemodynamic presentation of IMD are clinically and prognostically distinct. Recognition of these phenotypes is critical for appropriate management and prediction of outcome.
3. Soluble Fms-Like Tyrosine Kinase-1 Associates With Risk of Acute Respiratory Distress Syndrome and Mortality in Sepsis.
In a prospective sepsis cohort (n=198), higher early plasma sFlt-1 measured in the ED was associated with increased risk of ARDS (OR 1.91 per log increase) and mortality (OR 2.19 per log increase). Causal mediation analysis indicated that ARDS mediated approximately 20% of the sFlt-1–mortality relationship, implicating VEGF pathway dysregulation as an endothelial target.
Impact: Links an early, mechanistically plausible endothelial biomarker to ARDS and mortality with mediation analysis, supporting sFlt‑1/VEGF as a potential therapeutic target in sepsis-associated ARDS.
Clinical Implications: Early sFlt‑1 testing could aid risk stratification for sepsis-associated ARDS and mortality, informing monitoring, ventilatory strategies, and enrollment in endothelial-targeted trials.
Key Findings
- Early plasma sFlt-1 levels (ED admission) were associated with ARDS risk (OR 1.91 per log increase; p<0.01).
- sFlt-1 was associated with mortality in sepsis (OR 2.19 per log increase; p<0.01).
- ARDS mediated 20.3% of the total effect of sFlt-1 on mortality (p<0.01), implicating the VEGF pathway.
- ARDS developed in 29% of patients within 6 days of admission.
Methodological Strengths
- Prospective cohort with early biomarker sampling at ED arrival and standardized ARDS definitions.
- Adjusted logistic regression and causal mediation analysis strengthen inference.
Limitations
- Single-center enrollment and modest sample size may limit generalizability.
- Sepsis-2 criteria used; external validation under Sepsis-3 is needed.
Future Directions: Validate sFlt‑1 thresholds across centers and Sepsis‑3 cohorts; test anti‑VEGF/sFlt‑1–modulating strategies in sepsis‑associated ARDS trials.
IMPORTANCE: The vascular endothelial growth factor (VEGF) signaling pathway is important in the pathogenesis of acute respiratory distress syndrome (ARDS) with supportive genetic and proteomic evidence. Genetic polymorphisms within FLT1, which encodes VEGF receptor 1, associate with risk of ARDS in sepsis. Soluble Fms-like tyrosine kinase-1 (sFlt-1) is a secreted splice variant of FLT1 that acts as a potent antagonist to circulating VEGF. OBJECTIVES: To assess the association between early plasma concentrations of sFlt-1 and risk of ARDS and to determine if ARDS mediates the relationship between sFlt-1 and mortality during sepsis. DESIGN, SETTING, AND PARTICIPANTS: In a prospective cohort study, we enrolled 198 critically ill patients with sepsis per Sepsis-2 criteria. ARDS was defined per Berlin criteria. MAIN OUTCOMES AND MEASURES: Levels of sFlt-1 were quantified using electrochemiluminescence on plasma collected in the emergency department upon admission. We tested the association between plasma levels of sFlt-1 with ARDS and mortality using logistic regression adjusting for age, sex, and pulmonary versus nonpulmonary source of sepsis. We applied causal mediation analysis to determine the percentage of the total effect of sFlt-1 on mortality that was mediated by ARDS. RESULTS: We enrolled 198 patients; ARDS developed within 6 days in 29%. Plasma levels of sFlt-1 were significantly associated with risk of ARDS in sepsis (odds ratio [OR], 1.91 per log increase; 95% CI, 1.31-2.76 per log increase; p < 0.01). Plasma sFlt-1 levels were also associated with mortality (OR, 2.19 per log increase; 95% CI, 1.57-3.08 per log increase; p < 0.01). ARDS mediated 20.3% (95% CI, 6.9-98.1%) of the total effect of sFlt-1 on mortality (p < 0.01). CONCLUSIONS AND RELEVANCE: Higher plasma levels of sFlt-1 were associated with an increased risk of ARDS and ARDS mediated a significant proportion of the sFlt-1-associated mortality observed during sepsis. Our findings further implicate dysregulated VEGF signaling in ARDS and suggest that plasma sFlt-1 merits further investigation as an early endothelial therapeutic target for sepsis-associated ARDS and mortality.